Diabetic Retinopathy R&D Services
Diabetic retinopathy is a major complication of diabetes. Understanding the disease mechanisms of diabetic retinopathy and developing novel therapies and diagnostics have become urgent needs for the industry. Ace Therapeutics is a professional contract research organization that is deeply involved in preclinical diabetes research. Leveraging extensive diabetic retinopathy models and preclinical development services, we provide one-stop solutions for the development of drugs and medical devices targeting diabetic retinopathy. We are committed to collaborating with clients to overcome R&D bottlenecks and accelerate the translation of innovative discoveries into clinical applications.
Introduction to Diabetic Retinopathy
Diabetic retinopathy is a serious microvascular complication induced by diabetes. Sustained hyperglycemia induces vascular damage and leakage in the retina, progressing to microaneurysms and neovascularization, ultimately leading to irreversible vision loss or even blindness. With the rising global prevalence of diabetes, diabetic retinopathy (DR) has become the leading cause of blindness in the working-age population. However, current DR therapies remain limited, early intervention strategies are scarce, and there is an urgent unmet need for safe and efficacious innovative therapies.
Fig. 1 Clinical and histological perspective on diabetic retinopathy. (Lechner, J.; et al., 2017)
Diabetic Retinopathy R&D Services at Ace Therapeutics
Ace Therapeutics leverages its cutting-edge translational research platform for diabetic retinopathy to deliver innovative, end-to-end solutions spanning the entire disease continuum. By deeply integrating pathological mechanism research with translational science insights, we empower clients to accelerate the development of next-generation therapies with differentiated clinical value.
Relying on our rich modeling experience and in-depth understanding of DR pathology, we provide clients with a diversified animal model system to facilitate precise scientific research.
| Model |
Features |
Applications |
| NOD spontaneous diabetic mouse model |
Spontaneous type 1 diabetes with significant gender differences. |
Drug screening and pathological validation |
| STZ-induced SD rat model |
Low cost and short cycle time |
Studying the pathogenesis of diabetic retinopathy and therapeutic agents. |
Our experienced experts provide in-depth analysis of the pathogenesis of DR and help clients carry out systematic research from molecular, cellular and tissue dimensions.
- By leveraging gene expression profiling (qPCR, RNA-seq), proteomics, and metabolomics, we uncover hyperglycemia-induced vascular damage, inflammatory responses, and oxidative stress-related signaling pathways (e.g., VEGF, Akt/mTOR, NF-κB pathways).
- Through retinal cell co-culture models (endothelial cells, pericytes, retinal ganglion cells) and organoid models, we recapitulate pathological microenvironments to investigate intercellular interaction mechanisms.
- Utilizing CRISPR-Cas9 gene editing, we validate key gene functions at cellular and animal levels, providing a robust scientific foundation for therapeutic target discovery and drug development.
We provide one-stop therapeutic development services from target validation to preclinical efficacy evaluation.
- We conduct efficacy evaluations of drugs or devices targeting DR using customized animal models (STZ-induced mouse DR model, diabetic rhesus monkey model, transgenic model).
- We quantify retinal vascular lesions and structural changes by fundus fluorescence angiography (FFA) and optical coherence tomography (OCT).
- We assess visual function improvement with the help of electroretinography (ERG), visual behavioral tests.
- We test molecular indicators such as inflammatory factors and oxidative stress markers to comprehensively assess treatment effects.
- We conduct ocular local and systemic safety evaluations.
We utilize multi-omics technologies and bioinformatics analysis platforms, and are committed to helping our clients screen for highly specific DR biomarkers.
- We conduct comprehensive analysis of animal model samples (atrial fluid, vitreous humor, blood) to uncover potential markers (e.g., sICAM-1, 8-OHdG, miRNA-126) related to the development of DR, disease staging, and treatment response.
- Through large sample validation, we assess the diagnostic accuracy and prognostic value of the biomarkers, and help our clients to develop new non-invasive and convenient methods for early diagnosis of DR.
Ace Therapeutics specializes in early diagnosis and precision assessment of diabetic retinopathy (DR), delivering end-to-end services from technology development through product commercialization to advance therapeutic innovations. By integrating optical coherence tomography angiography (OCTA) and fundus fluorescein angiography (FFA) imaging technologies, we optimize image analysis workflows to enhance the sensitivity and specificity of lesion detection. Furthermore, we assist clients in diagnostic product development by conducting performance validation and supporting preclinical regulatory submissions, accelerating the translation of innovative diagnostic technologies from laboratory research to clinical implementation.
Advantages of Our Diabetic Retinopathy R&D Services
- Experienced interdisciplinary teams customize scientific and efficient R&D solutions for clients from the perspective of their needs.
- We establish a full-process quality control system covering experimental design, sample collection, data processing and analysis.
- Our services cover a wide range of areas such as therapeutic drug development, diagnostic technology innovation, and biomarker discovery.
Ace Therapeutics is committed to utilizing our experience and expertise in the field of diabetic retinopathy to provide comprehensive preclinical solutions for our clients. Please contact us for more details and we will be happy to assist you.
References
- Lechner, J.; et al. The pathology associated with diabetic retinopathy. Vision research. 2017, 139: 7-14.
- Tan, T. E. & Wong, T. Y. Diabetic retinopathy: Looking forward to 2030. Frontiers in Endocrinology. 2023, 13: 1077669.
- Wang, W. & Lo, A. C. Y. Diabetic retinopathy: pathophysiology and treatments. International journal of molecular sciences. 2018, 19(6): 1816.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
